Fintel reports that on September 24, 2024, Baird downgraded their outlook for McKesson (NYSE:MCK) from Outperform to Neutral.

Robert W. Baird analyst Eric Coldwell downgraded the rating on McKesson (MCK – Research Report) to a Hold today, setting a price target ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Today, Benzinga's options scanner identified 12 options transactions for McKesson. This is an unusual occurrence. The ...

McKesson, a drug distributor and medical-products company, will own a 70% stake in the company. Back To Top ...

McKesson boasts solid revenue and EPS growth, supported by AI integration. Click here to read what offers a compelling ...

The Zacks Medical - Dental Supplies industry, to which McKesson belongs, has gained 0.9% over this period. Now the key question is: Where could the stock be headed in the near term? While media ...

McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings ...

McKesson, a drug distributor and medical-products company, will own a 70% stake in the company. Core Ventures was set up by Florida Cancer Specialists & Research Institute, LLC, a physician-owned ...